Patterns of Failure and Survival Trends in 3,808 Patients with Stage II Nasopharyngeal Carcinoma Diagnosed from 1990 to 2012: A Large-Scale Retrospective Cohort Study
- Author:
Xue Song SUN
1
,
2
;
Di Han LIU
;
Sai Lan LIU
;
Qiu Yan CHEN
;
Shan Shan GUO
;
Yue Feng WEN
;
Li Ting LIU
;
Hao Jun XIE
;
Qing Nan TANG
;
Yu Jing LIANG
;
Xiao Yun LI
;
Jin Jie YAN
;
Ming Huang HONG
;
Jun MA
;
Lin Quan TANG
;
Hai Qiang MAI
Author Information
- Publication Type:Original Article
- Keywords: Nasopharyngeal carcinoma; Radiotherapy; Prognosis
- MeSH: Cohort Studies; Diagnosis; Disease-Free Survival; Drug Therapy; Follow-Up Studies; Humans; Neoplasm Metastasis; Prognosis; Radiotherapy; Retrospective Studies; Survival Rate
- From:Cancer Research and Treatment 2019;51(4):1449-1463
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The purpose of this study was to investigate the survival trends and patterns of failure in patients with stage II nasopharyngeal carcinoma (NPC) treated with radiotherapy (RT) and chemotherapy over the last 20 years. MATERIALS AND METHODS: Thirty-eight hundred and eight patients diagnosed with stage II NPC between January 1990 and December 2012 were involved in this retrospective cohort study. All patients were treated with RT. According to the main imaging techniques and RT technology, we categorized these patients into four calendar periods: 1990-1996, 1997-2002, 2003-2007, and 2008-2012. Overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRFS), and distant metastasis–free survival (DMFS) were served as the clinical outcome. RESULTS: After a median follow-up period of 84.7 months, we observed increasing trends in survival and disease control. The 3- and 5-year OS rates increased from 87.1% and 78.7% in the first calendar period to 97.4% and 94.5% in the last calendar period, respectively (p<0.001). Additionally, significant increasing trends could be seen in the PFS and LRFS during the four calendar periods. In the subgroup analysis, the LRFS in patients older than 50 years at diagnosis showed greater improvement than younger patients. However, the rate of distant metastasis was stable and relatively low, as the 5-year DMFS ranged from 90.5% to 94.7% among the four calendar periods. CONCLUSION: The survival rates in patients with stage II NPC showed increasing trends from 1990 to 2012. The advance of RT provided excellent locoregional control and enhanced OS.
